Business Wire

NTT-ELECTRONICS

16.9.2022 08:01:41 CEST | Business Wire | Press release

Share
NTT Electronics expands its 400G Coherent DSP line-up into Data Center Interconnects and longer reach networks

NTT Electronics Corporation, a leading supplier of coherent Digital Signal Processor (DSP) solutions to system and module manufacturers worldwide, today announced addition of a low power consumption 400G Coherent DSP to its product portfolio for enabling multi-rate Ethernet transport and applications far beyond Data Center Interconnects. The new DSP ExaSPEED400-R focuses on 400ZR and OpenZR+ interoperable QSFP-DD applications, and achieves 20% less power consumption than its upper-compatible ExaSPEED400 for CFP2-DCO applications.

The new ExaSPEED400-R supports both OIF 400ZR and OpenZR+ MSA 100G-400G specification at the line side, and provides Ethernet transport with 8x25G-NRZ and 8x50G-PAM4 interfaces at the client side. It supports fully flexible Ethernet formats: 1x100GE, 2x100GE/1x200GE, 3x100GE, and 4x100GE/2x200GE/1x400GE.

“This is a very exciting development enabling the use of a low-power DSP in interoperable coherent QSFP-DD modules for an expansion of the application space by cloud network operations and service providers,” said Atul Srivastava, Co-chair of the OpenZR+ MSA Group.

At ECOC 2022, NTT Electronics will show a video demonstration of QSFP-DD module interoperability at 400G OpenZR+ including over 1000km straight fiber transmission, with the support of its QSFP-DD partners Fujitsu Optical Components Ltd., Molex LLC, and NEC Corporation.

Mogi Masahiro, President, Fujitsu Optical Components America Inc, commented as below. “For many years, from the inception of the coherent optical transmission technology, NTT Electronics and Fujitsu Optical Components (FOC) have established a successful partnership to bring the most advanced optical transceiver products to market. We are now very pleased that interoperable coherent transmission has been achieved successfully between FOC’s QSFP-DD optical transceiver, incorporating NTT Electronics’ new ExaSPEED400-R DSP chip, and multi-vendors’ QSFP-DD transceivers. Using FOC’s optical transceiver which enables transmission distance extension with low-power consumption, we are very pleased to be contributing to the ecosystem of interoperable coherent transceivers for data center and service provider networks.”

“Molex is focused on expanding the reach for data center interconnect beyond 120km, recognizing the industry need for significantly improved performance,” said Joseph Chon, director, Coherent Technology and Product Line Management, Molex Optoelectronics. “Collaborating with NTT Electronics and its module partners has accelerated the overall business opportunity for the interoperable QSFP-DD Interconnect Systems and we look forward to supporting evolving customer requirements in this space.”

“We have been developing and producing the state-of-art digital coherent transceivers for more than a decade.” said Akio Goto, General Manager of Photonic Device Development Department, NEC, “And now, as part of continuous collaborations to expand the digital coherent business with NTT Electronics, we have succeeded in developing QSFP-DD, competitive in the market, by using our technical assets and experience. We are accelerating their deployments for various markets.”

ExaSPEED400-R is now ramping up its production volume.

About NTT Electronics

NTT Electronics has been developing and commercializing optical communications devices since 1995. It has complete portfolio of optical and electronics products to cover the industry needs for 100G-and-beyond systems, ROADM components and FTTH networks. Since 2012 NTT Electronics has been delivering its flag-ship 100G coherent DSP that has been widely adopted in the industry. NTT Electronics is headquartered in Yokohama, Japan with offices in Milan, Italy, San Jose, CA, and Shenzhen, China. For more information, go to http://www.ntt-electronics.com/en/about/overview.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005082/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye